William Blair research analyst Margaret Kaczor was quoted in MedTech Insight’s coverage of the innovations happening in cardiovascular health technology advancements and what they mean for the industry and investors.
Equity Research
Margaret Kaczor Discusses Cardiovascular Company News and Trends in MedTech Insight
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights
Our Latest News
-
Aardvark Therapeutics, Inc.: Initiation of Research Coverage
William Blair initiated research coverage of Aardvark Therapeutics, Inc. (AARD $13.98). Aardvark is advancing ARD-101, an oral therapy that targets bitter taste receptors (TAS2Rs) in the gastrointestinal tract, and ARD-201, a combination of ARD-101 and a DPP-4 inhibitor, for treating Prader-Willi syndrome (PWS) and obesity, respectively.
-
-